RT Journal Article
SR Electronic
T1 Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in males
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.04.20225680
DO 10.1101/2020.11.04.20225680
A1 Baldassarri, Margherita
A1 Picchiotti, Nicola
A1 Fava, Francesca
A1 Fallerini, Chiara
A1 Benetti, Elisa
A1 Daga, Sergio
A1 Valentino, Floriana
A1 Doddato, Gabriella
A1 Furini, Simone
A1 Giliberti, Annarita
A1 Tita, Rossella
A1 Amitrano, Sara
A1 Bruttini, Mirella
A1 Croci, Susanna
A1 Meloni, Ilaria
A1 Pinto, Anna Maria
A1 Gabbi, Chiara
A1 Sciarra, Francesca
A1 Venneri, Mary Anna
A1 Gori, Marco
A1 Sanarico, Maurizio
A1 Crawley, Francis P.
A1 Pagotto, Uberto
A1 Fanelli, Flaminia
A1 Mezzullo, Marco
A1 Dominguez-Garrido, Elena
A1 Planas-Serra, Laura
A1 Schlüter, Agatha
A1 Colobran, Roger
A1 Soler-Palacin, Pere
A1 Lapunzina, Pablo
A1 Tenorio, Jair
A1 Spanish Covid HGE
A1 Pujol, Aurora
A1 Castagna, Maria Grazia
A1 Marcelli, Marco
A1 Isidori, Andrea M.
A1 GEN-COVID Multicenter Study
A1 Renieri, Alessandra
A1 Frullanti, Elisa
A1 Mari, Francesca
YR 2020
UL http://medrxiv.org/content/early/2020/11/05/2020.11.04.20225680.abstract
AB Background COVID-19 presentation ranges from asymptomatic to fatal. The variability in severity may be due in part to impaired Interferon type I response due to specific mutations in the host genome or to autoantibodies, explaining about 15% of the cases when combined. Exploring the host genome is thus warranted to further elucidate disease variability.Methods We developed a synthetic approach to genetic data representation using machine learning methods to investigate complementary genetic variability in COVID-19 infected patients that may explain disease severity, due to poly-amino acids repeat polymorphisms. Using host whole-exome sequencing data, we compared extreme phenotypic presentations (338 severe versus 300 asymptomatic cases) of the entire (men and women) Italian GEN-COVID cohort of 1178 subjects infected with SARS-CoV-2. We then applied the LASSO Logistic Regression model on Boolean gene-based representation of the poly-amino acids variability.Findings Shorter polyQ alleles (≤22) in the androgen receptor (AR) conferred protection against a more severe outcome in COVID-19 infection. In the subgroup of males with age <60 years, testosterone was higher in subjects with AR long-polyQ (≥23), possibly indicating receptor resistance (p=0.004 Mann-Whitney U test). Inappropriately low testosterone levels for the long-polyQ alleles predicted the need for intensive care in COVID-19 infected men. In agreement with the known anti-inflammatory action of testosterone, patients with long-polyQ (≥23) and age>60 years had increased levels of C Reactive Protein (p=0.018).Interpretation Our results may contribute to design reliable clinical and public health measures and provide a rationale to test testosterone treatment as adjuvant therapy in symptomatic COVID-19 men expressing AR polyQ longer than 23 repeats.Funding MIUR project “Dipartimenti di Eccellenza 2018-2020” to Department of Medical Biotechnologies University of Siena, Italy (Italian D.L. n.18 March 17, 2020). Private donors for COVID research and charity funds from Intesa San Paolo.Evidence before this study We searched on Medline, EMBASE, and Pubmed for articles published from January 2020 to August 2020 using various combinations of the search terms “sex-difference”, “gender” AND SARS-Cov-2, or COVID. Epidemiological studies indicate that men and women are similarly infected by COVID-19, but the outcome is less favorable in men, independently of age. Several studies also showed that patients with hypogonadism tend to be more severely affected. A prompt intervention directed toward the most fragile subjects with SARS-Cov2 infection is currently the only strategy to reduce mortality. glucocorticoid treatment has been found cost-effective in improving the outcome of severe cases. Clinical algorithms have been proposed, but little is known on the ability of genetic profiling to predict outcome and disclose novel therapeutic strategies.Added-value of this study In a cohort of 1178 men and women with COVID-19, we used a supervised machine learning approach on a synthetic representation of the uncovered variability of the human genome due to poly-amino acid repeats. Comparing the genotype of patients with extreme manifestations (severe vs. asymptomatic), we found that the poly-glutamine repeat of the androgen receptor (AR) gene is relevant for COVID-19 disease and defective AR signaling identifies an association between male sex, testosterone exposure, and COVID-19 outcome. Failure of the endocrine feedback to overcome AR signaling defect by increasing testosterone levels during the infection leads to the fact that polyQ becomes dominant to T levels for the clinical outcome.Implications of all the available evidence We identify the first genetic polymorphism predisposing some men to develop a more severe disease irrespectively of age. Based on this, we suggest that sizing the AR poly-glutamine repeat has important implications in the diagnostic pipeline of patients affected by life-threatening COVID-19 infection. Most importantly, our studies open to the potential of using testosterone as adjuvant therapy for severe COVID-19 patients having defective androgen signaling, defined by this study as ≥23 PolyQ repeats and inappropriate levels of circulating androgens.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04549831Clinical Protocols http://www.nig.cineca.it https://www.covid19hg.org Funding StatementMIUR project-Dipartimenti di Eccellenza 2018-2020- to Department of Medical Biotechnologies University of Siena, Italy (Italian D.L. n.18 March 17, 2020). Private donors for COVID research and charity funds from Intesa San Paolo.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The GEN-COVID study was approved by the University Hospital of Siena Ethics Review Board (Protocol n. 16917, dated March 16, 2020). This observational study has been inserted in www.clinicaltrial.org (NCT04549831). The Spanish CovidHGE cohort is under IRB approval PR127/20 from Bellvitge University Hospital, Barcelona Spain.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data and samples referenced here are housed in the GEN-COVID Patient Registry and the GEN-COVID Biobank and are available for consultation. For further information, you may contact the corresponding author, Prof. Alessandra Renieri (e-mail: alessandra.renieri{at}unisi.it). http://www.nig.cineca.it https://www.covid19hg.org